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Long-term double-blind studyDaytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may
impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the
long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance
during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, random-
ized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and
health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computer-
ized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively. Treatment with ﬂexible-dose
lurasidone40–160mg/d, administeredoncedaily in theevening,was associatedwith signiﬁcantly reducedday-
time sleepiness compared with ﬂexibly dosed quetiapine XR 200–800 mg/d (p= 0.03, effect size= 0.36) at
week 32 (month 6 of the continuation study endpoint). Incidence of markedly high sleepiness (ESS N10)
was signiﬁcantly higher in the quetiapine XR (200–800 mg/d) group compared with the lurasidone
(40–160 mg/day) group at both months 3 and 6 visits (p b 0.05). Lurasidone (40–160 mg/d) signiﬁcantly im-
provedneurocognitive performance compared to quetiapineXR (200–800mg/d) before (effect size=0.49)
and after adjustment (effect size=0.45) for sleepiness effect (p=0.008 and 0.010, respectively). Increased
daytime sleepinesswas signiﬁcantly associatedwith reduced neurocognitive performance (p=0.019) and
quality of well-being (p= 0.05). Our ﬁndings suggest that clinicians should actively monitor patients for
the presence of daytime sleepiness due in part to its potential impact on neurocognitive performance
and well-being.ofMedicine, Sunovion
Jersey 07024. Tel.: +1
ebel).
. This is an open access© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Daytime sleepiness adversely impacts neurocognitive perfor-
mance, which is often signiﬁcantly impaired in patients with schizo-
phrenia (Kane and Sharif, 2008; Leifker et al., 2009; Hawley et al.,
2010; Wilson and Argyropoulos, 2012; Loebel et al., 2013a). Daytime
sleepiness is a commonly reported adverse effect of pharmacologicPhar-
201
article unagents with signiﬁcant antihistaminergic and/or antiserotonergic ef-
fects, such as certain antipsychotic agents. The propensity to doze
while performing daily activities such as driving or working can
have serious consequences, including increased motor vehicle and
work-related accidents, as well as compromised job performance
(National Sleep Foundation, 2007; American Academy of Sleep Med-
icine 2009). It has been estimated that driving while drowsy contrib-
utes to 100,000 police-reported crashes that resulted in 71,000
injuries and 1550 deaths each year in the United States (National
Sleep Foundation, 2007). Daytime sleepiness, if persistent, can ad-
versely impact patients' social and daily functioning, quality of life
and can compromise treatment adherence (Kane and Sharif, 2008;
McWhirter et al. 2007). Despite awareness of the health and economic
burden posed by daytime sleepiness, the long-term effects ofder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consequences have not been adequately studied (Kane and Sharif,
2008; McWhirter et al. 2007).
Lurasidone is a novel benzisothiazol derivative with potent bind-
ing afﬁnity for the D2, 5-HT2A and 5HT7 receptors (antagonist), and
moderate afﬁnity for 5HT1A (partial agonist) and α2C receptors (an-
tagonist) (Ishibashi et al., 2010; Horiguchi et al., 2011). Lurasidone
has no appreciable afﬁnity for H1 and M1 receptors (Ishibashi et al.,
2010). In contrast, quetiapine is associated with a high afﬁnity at
the H1 receptor where it acts as an antagonist (Baldwin and Scott,
2009); this mechanism is associated with sedation in both animal
models and human studies (Witek et al., 1995). The short-term ef-
fects of lurasidone on neurocognitive performancewere demonstrat-
ed in a 3-week double-blind, active-controlled study of lurasidone
and ziprasidone (Harvey et al., 2011), as well as a 6-week, double-
blind, placebo- and active-controlled study of lurasidone and
quetiapine XR (Harvey et al., 2013). In a 6-month, double-blind,
ﬂexible-dose, continuation study, lurasidone (40–160mg/d) was su-
perior to quetiapineXR (200–800mg/d) for cognitive performance at
both months 3 and 6 of the extension study (Harvey et al., 2013,
2015). The objective of this post-hoc analysis was to evaluate the
long-term effects of ﬂexible-dose lurasidone 40–160 mg/d and
quetiapine XR 200–800 mg/d on daytime sleepiness, and the impact
of daytime sleepiness on neurocognitive performance in a long-term
continuation study that followed a 6-week acute trial in patients with
schizophrenia.2. Methods
The analysis reported here is based on data from a previously re-
ported randomized, double-blind, 6-week, placebo- and active-
controlled acute study (Loebel et al., 2013b), followed by a double-
blind continuation study that continued up to 1 year (Loebel et al.,
2013c). The design of these studieswill therefore only be brieﬂy sum-
marized here. The study was approved by an institutional review
board at each investigational site and was conducted in accordance
with the International Conference on Harmonisation of Good Clinical
Practices guidelines, andwith the ethical principles of theDeclaration
of Helsinki. All patients signed an informed consent document
explaining study procedures and potential risks before study entry.2.1. Patients
Patients with a primary diagnosis of schizophrenia, who had re-
cently been hospitalized for an acute exacerbation of psychotic symp-
toms, were randomly assigned to receive 6 weeks of double-blind
treatment with once-daily ﬁxed doses of lurasidone (80 mg or
160 mg), quetiapine XR (600 mg), or placebo. Upon completion of
the initial 6-week study, eligible patients were enrolled in the 1-year,
double-blind, ﬂexible-dose, continuation study, where patients contin-
ued treatment with either lurasidone 40–160 mg/d (lurasidone-to-
lurasidone) or quetiapine XR 200–800 mg/d (quetiapine XR-to-
quetiapine XR). Cognitive and functional capacity assessments were
obtained at baseline and up to 6 months in the continuation study.
Patients who had been treated with placebo in the initial 6-week
study were switched in a blinded fashion to ﬂexible-dose lurasidone
treatment in the continuation study (placebo-to-lurasidone), but the
present analyses focused primarily on those patients receiving
lurasidone during both the acute and continuation study phases
(lurasidone-to-lurasidone). Entry into the continuation study required
patients to have completed all assessments on the ﬁnal week 6 visit of
the acute phase and to have been judged by the investigator as suitable
for continuation study treatment in an outpatient setting.2.2. Assessments
Daytime sleepiness was assessed using the Epworth Sleepiness
Scale (ESS), a validated self-reported measure of daytime sleepiness
at baseline, 6 weeks, and 3 and 6 months in the continuation treat-
ment phase (Johns, 1991, 2008). The total ESS score is the sum of
all 8 items (each refers to level of anticipated sleepiness in various
routine life situations) and ranges from 0 to 24. Each individual
item ranges from 0= ‘would never doze or sleep’ to 3 = ‘high chance
of dozingor sleeping’. Higher ESS scores are associatedwith a greater se-
verity of daytime sleepiness. If one ormore itemsweremissing at a visit,
the total score was set to missing. The ESS has been validated in both
case-controlled studies of normal patients and in a number of popula-
tions with various sleep disorders (Johns, 1991, 2008; Chervin, 2000).
Cognition was assessed by the CogState composite score (Pietrzak
et al., 2009) at baseline, week 6 (end of acute treatment phase), week
19 (month 3 of the continuation study), and week 32 (month 6 of
the continuation study). The composite measure of overall cognitive
performance was calculated as an average of the 7 standardized do-
main scores over the tasks of: Detection Task, Identiﬁcation Task, One
Back Task, International Shopping List Task, One Card Learning Task,
Groton Maze Learning Task, and the Social Emotional Cognition Task.
These standardized domain scores were computed using the age strat-
iﬁedCogState normativemean and standarddeviation according to the
following equation: (raw domain score – norm mean)/norm SD. The
sign of the standardized domain score was adjusted so that negative
scores indicated performance worse than average, and positive scores
indicated performance better than average. If three or more compo-
nents were missing at a visit, the CogState composite score was set to
missing. Health-related quality of life was measured using the Quality
of Well-Being (QWB-SA) Scale (Anderson et al., 1989).
2.3. Statistical methods
The primary treatment group comparison was between patients
continuing on ﬂexibly dosed lurasidone 40–160 mg/d (lurasidone-to-
lurasidone) or quetiapine XR 200–800 mg/d (quetiapine XR-to-
quetiapine XR) at week 19 and week 32 (month 3 and 6 of the contin-
uation study period). The change in neurocognitive composite score
frompretreatment baseline (week 0) toweek 19 andweek 32 (prima-
ry endpoint) was analyzed using a mixed-effects longitudinal data
analysis model (Fitzmaurice et al., 2004), with ﬁxed effects for treat-
ment, visit, baseline score, treatment-by-visit interaction, and study
sites. In addition,weevaluated the change from thepretreatment base-
line in the neurocognitive composite score after controlling for change
in ESS total score from baseline (week 0) over time. Cohen’s d be-
tween-group effect size was calculated as least squares mean differ-
ence between LUR-to-LUR and QXR-to-QXR divided by the model
estimate of the pooled SD (across treatment groups), adjusting for
site effects and baseline at randomization. A Generalized Estimating
Equation (GEE) model was applied to evaluate the incidence of mark-
edly high sleepiness.
3. Results
A total of 292 patients completed the 6-week acute phase and
were enrolled in the double-blind continuation study (Fig. 1). Figure
1 depicts the disposition of patients. The analyses reported herein
were based on full analysis sample, with 207 patients had cognitive
assessment data at week 19 or week 32 or both visits (month 3 or 6
of the continuation study period). The median doses at the 6-month
study endpoint in the continuation study for lurasidone
(lurasidone-to-lurasidone, n= 151) and quetiapine XR (quetiapine
XR-to-quetiapine XR, n=85) were 120 mg/d and 600 mg/d, respec-
tively. There were no signiﬁcant differences between the treatment
Fig. 1. Disposition of Subjects. LUR-to-LUR: Lurasidone 80 mg/d or 160 mg/d in the 6-week acute phase followed by ﬂexible-dose lurasidone 40-160 mg/d in the 6-month contin-
uation study; PBO-to-LUR: placebo in the 6-week acute phase followed by ﬂexible-dose lurasidone 40-160 mg/d in the 6-month continuation study; QXR-to-QXR: Quetiapine XR
600 mg/d in the 6-week acute phase followed by ﬂexible-dose quetiapine XR 200-800 mg/d in the 6-month continuation study.
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neurocognitive composite score and baseline daytime sleepiness
ESS score (Table 1).
The proportion of patientswho experiencedmarkedly high sleep-
iness (as assessed by ESS total score N10) was signiﬁcantly greater in
the quetiapine XR-to-quetiapine XR group compared to the
lurasidone-to-lurasidone group at both month 3 (16.4% vs. 7.5%,
z = 2.08, p = 0.038, NNT = 12) and month 6 (12.7% vs. 5.5%, z =
1.97, p = 0.049, NNT = 14) endpoints (Fig. 2). Change in ESS total
score from baseline to week 32 (month 6 of the continuation study)
signiﬁcantly favored the lurasidone-to-lurasidone group (LS mean
change −1.10, SE 0.26) compared to the quetiapine XR-to-
quetiapine XR group (LS mean change −0.07, SE 0.40) (p = 0.03,
t=−2.2; df= 748; effect size= 0.36) (Fig. 3).
Subjects treated with ﬂexible, once-daily doses of lurasidone
(40–160 mg) showed signiﬁcantly better cognitive performance
(assessed by the CogState computerized cognitive battery) compared
to quetiapine XR (200–800 mg) both before (effect size= 0.49) and
after adjustment (effect size = 0.45) for daytime sleepiness effect
(p= 0.008 and 0.010, respectively) (Fig. 4).
Reduction in daytime sleepiness (lower ESS total score) from
baseline was signiﬁcantly associated with improvement inTable 1
Demographics and clinical characteristics.
LUR80/160-LUR
n = 151
Age, mean (SD) 37.1 (12.3)
Gender, n (%)
Male 108 (72%)
Female 43 (28%)
Race, n (%)
White 87 (58%)
Black 22 (15%)
Asian/other 35 (23%)
Pretreatment PANSS total score 98.0 (10.6)
Mean (SD) N = 151
Pretreatment CogState composite score
Full analysis sample −3.90 (3.41)
Mean (SD) N = 137
Pretreatment ESS
Mean (SD) 5.80 (4.66)
Pretreatment QWB-SA
Mean (SD) 0.57 (0.19)neurocognitive performance over the double-blind, acute and contin-
uation study periods (p= 0.019, chi-square= 5.53, df= 258), with
an increase of 1.85 points in the ESS total score associated with a
0.1 (CogState composite score) worsening in neurocognitive perfor-
mance (Fig. 5). Reduction in daytime sleepiness from baseline was
also signiﬁcantly associated with improvement of the QWB-SA
score across the treatment groups (p = 0.05, chi-square = 3.83,
df= 236).
4. Discussion
In this post-hoc analysis of a long-term, active-controlled, double-
blind, continuation study that followed a 6-week acute trial, treat-
ment with ﬂexibly dosed lurasidone 40–160 mg/d, administered
once daily in the evening, was associated with signiﬁcantly less
daytime sleepiness compared with ﬂexibly dosed quetiapine XR
200–800 mg/d. Incidence of markedly high sleepiness was higher at
both weeks 19 (month 3 of the continuation study) and 32 (month
6 of the continuation study) in the quetiapine XR-to-quetiapine XR
group compared with the lurasidone-to-lurasidone group. These re-
sults are consistent with ﬁndings reported from the acute phase,
placebo-controlled study, where patients with schizophrenia werePBO-LUR QXR-QXR P-value
n = 56 n = 85
37.5 (11.2) 38.5(10.1) 0.847
35 (63%) 52 (61%) 0.248
21 (38%) 33 (39%)
32 (57%) 56 (66%) 0.500
8 (14%) 13 (15%)
16 (29%) 12 (14%)
96.6 (10.3) 97.8 (10.6) 0.685
N = 56 N = 85
−4.54 (3.48) −4.30 (3.62) 0.467
N = 54 N = 80
5.89 (4.38) 6.73 (3.92) 0.304
0.58 (0.21) 0.57 (0.19) 0.959
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Fig. 2. Rates of markedly high daytime sleepiness (ESS total score N10).
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and we extend these results by demonstrating that the excess day-
time sleepiness associated with quetiapine XR (vs. lurasidone)
persisted in the subsequent long-term continuation study.
The ﬁndings that quetiapine XR was associated with greater inci-
dence of markedly high sleepiness and reduced neurocognitive
performance at week 32 (end of 6 month continuation study) com-
pared with lurasidone suggest that tolerance and adaptation to this
drug-induced adverse effect did not occur over time. Signiﬁcantly
greater improvement from baseline to week 32 (month 6 of the con-
tinuation study) in favor of lurasidone compared with quetiapine XR
was observed in neurocognitive performance before and after adjust-
ment for daytime sleepiness effects.
We note that while the current study evaluated quetiapine XR,
similar comparative ﬁndings versus lurasidone would be expected
for quetiapine IR, which has been shown to be associatedwith higher
sedation intensity and less patient satisfaction compared to the XR
formulation (Datto et al., 2009; Riesenberg et al., 2012; Riedel et al.,
2015).Fig. 3. Epworth Sleepiness Scale Total Score Over 32Weeks of Follow-up (Mixed Effects Mod
by ﬂexible-dose lurasidone 40-160mg/d in the 6-month continuation study; QXR-to-QXR: Q
XR 200-800 mg/d in the 6-month continuation study.Across all treatment groups, we found that increased daytime
sleepiness was signiﬁcantly related to reduced neurocognitive per-
formance and quality of well-being, assessed over the acute phase
study and longer-term extension. Given that cognitive impairment
is both pervasive and relatively severe in patients with schizophrenia
(Kane and Sharif, 2008; Leifker et al., 2009), our ﬁndings suggest that
patientsmay be vulnerable to evenmodest levels of drug-induced se-
dation, due to its negative impact on cognition and well-being, and
that this should be avoided when possible.
Drug-induced sedation, including by antipsychotic agents, is
among the most common causes of excessive daytime sleepiness
(Kane and Sharif, 2008). However, this common clinical problem
has not been well-studied, so that the magnitude of antipsychotic-
induced daytime sleepiness and its impact on cognition and function-
ing are poorly understood. Our study contributes to further under-
standing of the comparative impact and longitudinal course of
daytime sleepiness associated with antipsychotic agents.
The ﬁndings reported here that increased daytime sleepiness was
signiﬁcantly associated with worsening in neurocognitive perfor-
mance and quality of well-being are consistent with previous reports
that show excessive daytime sleepiness may adversely affect person-
al well-being, functional and cognitive performance, including con-
centration and alertness (McWhirter et al., 2007; Kane and Sharif
2008; Wilson and Argyropoulos, 2012; Loebel et al., 2013a, Riedel
et al., 2015).
Despite the signiﬁcant health and economic burden associated
with daytime sleepiness for both individuals and society, its evalua-
tion is challenging due to the lack of consensus on systematic
methods of assessment. This study conﬁrms that the Epworth Sleep-
iness Scale, a validated, patient-reported assessment of daytime
sleepiness, is sensitive to drug-related changes in daytime sleepiness
in patients with schizophrenia. Our ﬁnding supports the use of the
Epworth Sleepiness Scale as a practical monitoring tool to assess
level of daytime sleepiness in patients with schizophrenia.
Several limitations of theseﬁndings should benoted. First, the pri-
mary analysis was focused on longitudinal changes from baseline to
individual follow-up visits in patients who had completed an initial
6-week, randomized, placebo-controlled trial comparing ﬁxed
doses of lurasidone or quetiapine XR. Therefore, no long-term data
were available for those patients who did not participate in theel). LUR-to-LUR: Lurasidone 80 mg/d or 160mg/d in the 6-week acute phase followed
uetiapine XR 600mg/d in the 6-week acute phase followed byﬂexible-dose quetiapine
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Fig. 4. Longitudinal relationship between change in daytime sleepiness and cognitive performance at month 6 of the double-blind continuation study.
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characteristics (age, gender, PANSS scores, neurocognitive composite
score, and ESS scores) were comparable between the treatment
groups in the continuation study (Table 1), and between the 292 pa-
tients entering the 6-month continuation study versus the original
randomized ITT population (Harvey et al., 2013). These data suggest
that the extension study population was representative of the ran-
domized ITT population. Second, potential biases due to practice ef-
fects and regression to the mean may confound the results. These
potential confounds were addressed through the use of activeLS
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Fig. 5. Effect of Lurasidone on Change in CogState Composite Score from Baseline to Month
the 6-week acute phase followed by ﬂexible-dose lurasidone 40-160mg/d in the 6-month co
dose lurasidone 40-160mg/d in the 6-month continuation study;QXR-to-QXR: QuetiapineX
mg/d in the 6-month continuation study.controls in the double-blind, acute and continuation study phases
over an extended treatment period (up to 32 weeks) (Allison et al.,
2009), permitting valid comparisons of outcomes in the continuation
study. Pseudospeciﬁcity issues were also addressed by adjustment for
clinical symptoms (Harvey et al., 2013) or daytime sleepiness effects
with consistent results in all ﬁndings.
In summary, treatment with ﬂexible-dose lurasidone 40–160mg/d,
administered once daily in the evening,was associatedwith signiﬁcant-
ly less daytime sleepiness and signiﬁcantly improved neurocognitive per-
formance comparedwith ﬂexibly dosed quetiapine XR 200–800mg/dNo Adjustment for 
Sleepiness Improvement
Improvement
rasidone Quetiapine XR-to-Quetiapine XR
81 28 37
** Effect Size = 0.49
*P<0.05
**P<0.01
6 Endpoint of the Continuation Study. LUR-to-LUR: Lurasidone 80mg/d or 160 mg/d in
ntinuation study; PBO-to-LUR: placebo in the 6-week acute phase followed by ﬂexible-
R 600mg/d in the 6-week acute phase followedbyﬂexible-dose quetiapineXR200-800
12 P.D. Harvey et al. / Schizophrenia Research: Cognition 5 (2016) 7–12in a long-term continuation study that followed a 6-week acute trial
in patients with schizophrenia. Across all treatment groups, in-
creased daytime sleepinesswas signiﬁcantly associatedwith reduced
neurocognitive performance and quality of well-being over the acute
and continuation study periods. Clinicians should therefore actively
monitor patients for the presence of daytime sleepiness due in part
to its potential for adverse impact on neurocognitive performance
and well-being.
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